Samit Hirawat, Bristol Myers Squibb CMO

Bris­tol My­ers Squibb, blue­bird land once-high-stakes ap­proval on BC­MA CAR-T — and it bodes well for ri­val J&J

Al­most a year af­ter get­ting slammed by a sur­prise refuse-to-file let­ter, Bris­tol My­ers Squibb and blue­bird have been cleared to mar­ket the first BC­MA CAR-T ther­a­py.

Once a close­ly-watched event, the ap­proval of ide-cel in mul­ti­ple myelo­ma re­ceived a rel­a­tive­ly mut­ed wel­come when it was an­nounced Fri­day af­ter­noon. It was large­ly ex­pect­ed by an­a­lysts, who were how­ev­er sur­prised by parts of the la­bel.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.